We also found rs2071346 (G>T) variant genotype carriers were subjected to higher risk of anemia (GT <i>vs</i> GG, OR=1.665, P=0.022) and thrombocytopenia (GT <i>vs</i> GG, OR=1.685, P=0.035).
We determined that one SNP allele (rs3824120) in a CpG island associated with MYC which eliminated a CpG was more common in the cancer datasets than in the 100Genomes databases (p < 0.01).
We found two SNPs rs4645948 (C>T) and rs2071346 (G>T) were significantly associated with increased risk of developing NPC (TT+CT <i>vs</i> CC, OR=1.557, P=3.34×10<sup>-4</sup>; TT+GT <i>vs</i> GG, OR=1.361, P=0.007, respectively).
These findings suggested that individual carrying the rs4645948 T allele may be at greater risk for NPC due to an increase of MYC transcriptional activity and an augment of MYC expression.
We determined that one SNP allele (rs3824120) in a CpG island associated with MYC which eliminated a CpG was more common in the cancer datasets than in the 100Genomes databases (p < 0.01).
A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05-2.26, p = 0.028).
In addition, rs4645948 (C>T) was conferred with increased risk of anemia (CT <i>vs</i> CC, OR=2.152, P=0.001) and severe leukopenia (CT <i>vs</i> CC, OR=1.893, P=0.034) for NPC patients receiving chemoradiotherapy.